Author(s) Ali Z.; Al-Janabi A.; Warren R.B.; Matthews R.
Source Expert Review of Clinical Immunology; 2021; vol. 17 (no. 10); p. 1073-1081 Language English Publication Date 2021 DOI 10.1080/1744666X.2021.1967748 ISSN 1744-666X Database EMBASE Abstract Introduction: Interleukin (IL)-17 is critical in the pathogenesis of psoriasis and psoriatic arthritis (PsA) with most data suggesting that IL-17A alone was the key cytokine. However, in vitro and in vivo studies have suggested dual blockade of IL-17A and IL-17 F may be more effective than IL-17 A blockade alone. Bimekizumab is the first human monoclonal antibody to exert simultaneous specific inhibition of IL-17A and IL-17 F, and has been studied in several phase II/III trials for psoriasis and PsA. Areas covered: Bimekizumab is not currently licensed for use. A literature search identified clinical trials examining the efficacy and safety of bimekizumab for psoriasis and PsA, and these were critically appraised. Expert opinion: Clinical trials of bimekizumab have been promising, demonstrating a rapid onset of response and superior efficacy compared to three currently licensed biologics: secukinumab, ustekinumab, and adalimumab. Bimekizumab maintains a high level of efficacy with maintenance dosing intervals of 8 weeks, compared with 4 weeks for currently licensed IL-17A antagonists. No unexpected adverse events have been identified, although mild-to-moderate fungal infections occur in approximately 10%. Studies over longer time periods involving additional active comparators would be valuable in further defining the role of bimekizumab amongst currently available treatments.
0 Comments
Leave a Reply. |
The following databases were searched:
EMBASE, MEDLINE, PsycINFO, BNI, CINAHL, to find ELHT staff publications Specialties
All
Archives
May 2022
|
Learning Centre Library
Royal Blackburn Teaching Hospital 01254 734312 or Ext 84312 library.blackburn@elht.nhs.uk Find us |
Mackenzie Library
Burnley General Teaching Hospital 01282 803114 or Ext. 13114 library.burnley@elht.nhs.uk Find us |
Staffed Opening Hours
Mon 08:30-16:30 Tue 08:30-16:30 Wed 08:30-16:30 Thu 08:30-16:30 Fri 08:30-16:00 24/7 access to both libraries is available - please see library staff
|